The volume and frequency of cross-border controversy is increasing across business sectors, driven by a convergence of disruptive trends. Transfer pricing consistently ranks as the most significant tax risk for companies responding to our annual transfer pricing survey. Companies in the life sciences sector are especially experiencing transfer pricing challenges from tax authorities and face growing uncertainty and elevated risks. Adapting to this environment will require agility and resilience, and life sciences companies should consider evaluating their transfer pricing approaches and internal tax controversy management systems and processes. Read more about the observed trend of increasingly contentious and complicated transfer pricing...